O	O	0	9	Induction	Induction	B-NP	NN	O	0	ROOT	O
O	O	10	12	of	of	B-PP	IN	O	1	NMOD	O
O	O	13	18	human	human	B-NP	JJ	O	8	NMOD	O
O	O	19	35	immunodeficiency	immunodeficiency	I-NP	NN	O	8	NMOD	O
O	O	36	41	virus	virus	I-NP	NN	O	8	NMOD	O
O	O	42	46	type	type	I-NP	NN	O	8	NMOD	O
O	O	47	48	1	1	I-NP	CD	O	8	NMOD	O
O	O	49	59	expression	expression	I-NP	NN	O	2	PMOD	O
O	O	60	62	in	in	B-PP	IN	O	8	NMOD	O
O	O	63	72	monocytic	monocytic	B-NP	JJ	B-cell_type	11	NMOD	B-cell_type
O	O	73	78	cells	cell	I-NP	NNS	I-cell_type	9	PMOD	I-cell_type
O	O	79	81	by	by	B-PP	IN	O	1	NMOD	O
O	O	82	94	Cryptococcus	Cryptococcus	B-NP	FW	O	14	NMOD	O
O	O	95	105	neoformans	neoformans	I-NP	FW	O	17	NMOD	O
O	O	106	109	and	and	O	CC	O	17	NMOD	O
O	O	110	117	Candida	Candida	B-NP	NNP	O	17	NMOD	O
O	O	118	126	albicans	albicans	I-NP	NNP	O	12	PMOD	O
O	O	126	127	.	.	O	.	O	1	P	O

O	O	129	136	Because	Because	B-SBAR	IN	O	32	VMOD	O
O	O	137	148	candidiasis	candidiasis	B-NP	NN	O	4	NMOD	O
O	O	149	152	and	and	I-NP	CC	O	4	NMOD	O
O	O	153	167	cryptococcosis	cryptococcosis	I-NP	NN	O	5	SUB	O
O	O	168	171	are	be	B-VP	VBP	O	1	SBAR	O
O	O	172	178	common	common	B-ADJP	JJ	O	5	PRD	O
O	O	179	181	in	in	B-PP	IN	O	6	AMOD	O
O	O	182	187	human	human	B-NP	JJ	O	10	NMOD	O
O	O	188	204	immunodeficiency	immunodeficiency	I-NP	NN	O	10	NMOD	O
O	O	205	210	virus	virus	I-NP	NN	O	16	NMOD	O
O	O	211	212	(	(	O	(	O	13	DEP	O
O	O	212	215	HIV	HIV	B-NP	NN	O	13	DEP	O
O	O	215	216	)	)	O	)	O	10	NMOD	O
O	O	216	217	-	-	B-NP	HYPH	O	16	NMOD	O
O	O	217	225	infected	infected	I-NP	JJ	O	16	NMOD	O
O	O	226	233	persons	person	I-NP	NNS	O	7	PMOD	O
O	O	233	234	,	,	O	,	O	32	P	O
O	O	235	238	the	the	B-NP	DT	O	19	NMOD	O
O	O	239	245	effect	effect	I-NP	NN	O	32	SUB	O
O	O	246	248	of	of	B-PP	IN	O	19	NMOD	O
O	O	249	261	Cryptococcus	Cryptococcus	B-NP	FW	O	22	NMOD	O
O	O	262	272	neoformans	neoformans	I-NP	FW	O	25	NMOD	O
O	O	273	276	and	and	O	CC	O	25	NMOD	O
O	O	277	284	Candida	Candida	B-NP	FW	O	25	NMOD	O
O	O	285	293	albicans	albicans	I-NP	FW	O	20	PMOD	O
O	O	294	296	on	on	B-PP	IN	O	19	NMOD	O
O	O	297	300	HIV	HIV	B-NP	NN	O	28	NMOD	O
O	O	301	311	expression	expression	I-NP	NN	O	26	PMOD	O
O	O	312	314	in	in	B-PP	IN	O	28	NMOD	O
O	O	315	324	monocytic	monocytic	B-NP	JJ	B-cell_type	31	NMOD	B-cell_type
O	O	325	330	cells	cell	I-NP	NNS	I-cell_type	29	PMOD	I-cell_type
O	O	331	334	was	be	B-VP	VBD	O	0	ROOT	O
O	O	335	343	examined	examine	I-VP	VBN	O	32	VC	O
O	O	343	344	.	.	O	.	O	32	P	O

O	O	345	356	Stimulation	Stimulation	B-NP	NN	O	23	NMOD	O
O	O	357	359	of	of	B-PP	IN	O	1	NMOD	O
O	O	360	363	the	the	B-NP	DT	O	5	NMOD	O
O	O	364	372	latently	latently	I-NP	RB	O	5	NMOD	O
O	O	373	376	HIV	HIV	I-NP	NN	O	15	NMOD	O
O	O	376	377	-	-	O	HYPH	O	15	P	O
O	O	377	385	infected	infect	B-NP	VBN	O	15	NMOD	O
O	O	386	400	myelomonocytic	myelomonocytic	I-NP	JJ	O	11	NMOD	O
O	O	401	405	cell	cell	I-NP	NN	O	11	NMOD	O
O	O	406	410	line	line	I-NP	NN	O	11	NMOD	O
O	O	411	413	OM	OM	I-NP	NN	O	12	NMOD	O
O	O	413	414	-	-	B-NP	HYPH	O	15	P	O
O	O	414	416	10	10	I-NP	CD	O	12	AMOD	O
O	O	416	417	.	.	I-NP	.	O	12	P	O
O	O	417	418	1	1	I-NP	CD	O	2	PMOD	O
O	O	419	423	with	with	B-PP	IN	O	15	NMOD	O
O	O	424	425	C	C	B-NP	NN	O	16	PMOD	O
O	O	425	426	.	.	O	.	O	23	P	O
O	O	427	437	neoformans	neoforman	B-NP	NNS	O	21	NMOD	O
O	O	438	441	and	and	I-NP	CC	O	21	NMOD	O
O	O	442	443	C	C	I-NP	NN	O	23	NMOD	O
O	O	443	444	.	.	I-NP	.	O	21	P	O
O	O	445	453	albicans	albican	I-NP	NNS	O	31	SUB	O
O	O	454	456	in	in	B-PP	IN	O	23	NMOD	O
O	O	457	460	the	the	B-NP	DT	O	26	NMOD	O
O	O	461	469	presence	presence	I-NP	NN	O	24	PMOD	O
O	O	470	472	of	of	B-PP	IN	O	26	NMOD	O
O	O	473	479	pooled	pool	B-NP	VBN	O	29	AMOD	O
O	O	480	485	human	human	I-NP	JJ	O	30	NMOD	O
O	O	486	491	serum	serum	I-NP	NN	O	27	PMOD	O
O	O	492	498	caused	cause	B-VP	VBD	O	0	ROOT	O
O	O	499	500	a	a	B-NP	DT	O	33	NMOD	O
O	O	501	506	ratio	ratio	I-NP	NN	O	36	NMOD	O
O	O	506	507	-	-	B-NP	HYPH	O	36	NMOD	O
O	O	507	516	dependent	dependent	I-NP	JJ	O	36	NMOD	O
O	O	517	525	increase	increase	I-NP	NN	O	31	OBJ	O
O	O	526	528	in	in	B-PP	IN	O	36	NMOD	O
O	O	529	532	HIV	HIV	B-NP	NN	O	39	NMOD	O
O	O	533	543	production	production	I-NP	NN	O	37	PMOD	O
O	O	543	544	.	.	O	.	O	31	P	O

O	O	545	554	Induction	Induction	B-NP	NN	O	7	NMOD	O
O	O	555	557	of	of	B-PP	IN	O	1	NMOD	O
O	O	558	561	HIV	HIV	B-NP	NN	O	2	PMOD	O
O	O	562	564	by	by	B-PP	IN	O	1	NMOD	O
O	O	565	566	C	C	B-NP	NN	O	4	PMOD	O
O	O	566	567	.	.	O	.	O	1	P	O
O	O	568	578	neoformans	neoforman	B-NP	NNS	O	8	SUB	O
O	O	579	582	was	be	B-VP	VBD	O	0	ROOT	O
O	O	583	591	enhanced	enhance	I-VP	VBN	O	8	VC	O
O	O	592	594	by	by	B-PP	IN	O	9	VMOD	O
O	O	595	599	anti	anti	B-NP	AFX	B-protein	14	NMOD	B-protein
O	O	599	600	-	-	I-NP	HYPH	I-protein	14	NMOD	I-protein
O	O	600	608	capsular	capsular	I-NP	JJ	I-protein	14	NMOD	I-protein
O	O	609	617	antibody	antibody	I-NP	NN	I-protein	10	PMOD	I-protein
O	O	617	618	,	,	O	,	O	8	P	O
O	O	619	624	while	while	B-SBAR	IN	O	8	VMOD	O
O	O	625	634	induction	induction	B-NP	NN	O	21	SUB	O
O	O	635	637	by	by	B-PP	IN	O	17	NMOD	O
O	O	638	642	both	both	B-NP	DT	O	20	NMOD	O
O	O	643	652	organisms	organism	I-NP	NNS	O	18	PMOD	O
O	O	653	656	was	be	B-VP	VBD	O	16	SBAR	O
O	O	657	666	inhibited	inhibit	I-VP	VBN	O	21	VC	O
O	O	667	669	by	by	B-PP	IN	O	22	VMOD	O
O	O	670	674	anti	anti	B-NP	AFX	O	29	NMOD	O
O	O	674	675	-	-	I-NP	HYPH	O	29	NMOD	O
T1	B-Protein	675	678	TNF	TNF	I-NP	NN	B-protein	29	NMOD	B-protein
T1	I-Protein	678	679	-	-	B-NP	HYPH	O	29	NMOD	O
T1	I-Protein	679	684	alpha	alpha	I-NP	SYM	O	29	NMOD	O
O	O	685	693	antibody	antibody	B-NP	NN	O	23	PMOD	O
O	O	693	694	.	.	O	.	O	8	P	O

O	O	695	697	In	In	B-PP	IN	O	14	VMOD	O
O	O	698	701	THP	THP	B-NP	NN	B-cell_line	5	NMOD	B-cell_line
O	O	701	702	-	-	B-NP	HYPH	I-cell_line	5	NMOD	I-cell_line
O	O	702	703	1	1	I-NP	CD	I-cell_line	5	NMOD	I-cell_line
O	O	704	709	cells	cell	I-NP	NNS	I-cell_line	1	PMOD	I-cell_line
O	O	710	721	transfected	transfecte	B-VP	VBN	O	5	NMOD	O
O	O	722	726	with	with	B-PP	IN	O	6	VMOD	O
T3	B-Entity	727	730	HIV	HIV	B-NP	NN	B-DNA	10	NMOD	B-DNA
T3	I-Entity	731	738	plasmid	plasmid	I-NP	NN	I-DNA	10	NMOD	I-DNA
T3	I-Entity	739	749	constructs	construct	I-NP	NNS	I-DNA	7	PMOD	I-DNA
O	O	749	750	,	,	O	,	O	14	P	O
O	O	751	755	both	both	B-NP	DT	O	13	NMOD	O
O	O	756	765	organisms	organism	I-NP	NNS	O	14	SUB	O
O	O	766	773	induced	induce	B-VP	VBD	O	0	ROOT	O
O	O	774	787	transcription	transcription	B-NP	NN	O	14	OBJ	O
O	O	788	792	from	from	B-PP	IN	O	15	NMOD	O
O	O	793	796	the	the	B-NP	DT	O	21	NMOD	O
T4	B-Entity	797	800	HIV	HIV	I-NP	NN	B-DNA	21	NMOD	B-DNA
T4	I-Entity	801	805	long	long	I-NP	JJ	I-DNA	21	NMOD	I-DNA
T4	I-Entity	806	814	terminal	terminal	I-NP	JJ	I-DNA	21	NMOD	I-DNA
T4	I-Entity	815	821	repeat	repeat	I-NP	NN	I-DNA	16	PMOD	I-DNA
O	O	822	826	that	that	B-NP	WDT	O	21	NMOD	O
O	O	827	830	was	be	B-VP	VBD	O	22	SBAR	O
O	O	831	840	dependent	dependent	B-ADJP	JJ	O	23	PRD	O
O	O	841	843	on	on	B-PP	IN	O	24	AMOD	O
O	O	844	850	intact	intact	B-NP	JJ	O	25	PMOD	O
T5,T6	B-Entity,B-Entity	851	853	NF	NF	I-NP	NN	B-DNA	31	NMOD	B-DNA
T5,T6	I-Entity,I-Entity	853	854	-	-	B-NP	HYPH	I-DNA	31	NMOD	I-DNA
T5,T6	I-Entity,I-Entity	854	860	kappaB	kappaB	I-NP	NN	I-DNA	31	NMOD	I-DNA
T5	I-Entity	861	868	binding	binding	I-NP	NN	I-DNA	31	NMOD	I-DNA
T5	I-Entity	869	878	sequences	sequence	I-NP	NNS	I-DNA	26	NMOD	I-DNA
O	O	878	879	.	.	O	.	O	14	P	O

O	O	880	884	Thus	Thus	B-ADVP	RB	O	10	VMOD	O
O	O	884	885	,	,	O	,	O	10	P	O
O	O	886	887	C	C	B-NP	NN	O	9	NMOD	O
O	O	887	888	.	.	O	.	O	9	NMOD	O
O	O	889	899	neoformans	neoforman	B-NP	NNS	O	7	NMOD	O
O	O	900	903	and	and	I-NP	CC	O	7	NMOD	O
O	O	904	905	C	C	I-NP	NN	O	9	NMOD	O
O	O	905	906	.	.	I-NP	.	O	7	P	O
O	O	907	915	albicans	albican	I-NP	NNS	O	10	SUB	O
O	O	916	923	enhance	enhance	B-VP	VBP	O	0	ROOT	O
O	O	924	927	HIV	HIV	B-NP	NN	O	12	NMOD	O
O	O	928	938	expression	expression	I-NP	NN	O	10	OBJ	O
O	O	939	941	in	in	B-PP	IN	O	12	NMOD	O
O	O	942	951	monocytic	monocytic	B-NP	JJ	B-cell_type	15	NMOD	B-cell_type
O	O	952	957	cells	cell	I-NP	NNS	I-cell_type	13	PMOD	I-cell_type
O	O	958	965	through	through	B-PP	IN	O	10	VMOD	O
O	O	966	967	a	a	B-NP	DT	O	28	NMOD	O
T2	B-Protein	968	971	TNF	TNF	I-NP	NN	B-protein	28	NMOD	B-protein
T2	I-Protein	971	972	-	-	B-NP	HYPH	O	28	NMOD	O
T2	I-Protein	972	977	alpha	alpha	I-NP	SYM	O	28	NMOD	O
O	O	977	978	-	-	I-NP	HYPH	O	20	P	O
O	O	979	982	and	and	I-NP	CC	O	28	NMOD	O
T7	B-Entity	983	985	NF	NF	I-NP	NN	B-protein	25	NMOD	B-protein
T7	I-Entity	985	986	-	-	I-NP	HYPH	I-protein	25	P	I-protein
T7	I-Entity	986	992	kappaB	kappaB	I-NP	NN	I-protein	28	NMOD	I-protein
O	O	992	993	-	-	I-NP	HYPH	O	28	NMOD	O
O	O	993	1002	dependent	dependent	I-NP	JJ	O	28	NMOD	O
O	O	1003	1012	mechanism	mechanism	I-NP	NN	O	16	PMOD	O
O	O	1012	1013	.	.	O	.	O	10	P	O

O	O	1014	1016	In	In	B-PP	IN	O	9	VMOD	O
O	O	1017	1020	HIV	HIV	B-NP	NN	O	5	NMOD	O
O	O	1020	1021	-	-	O	HYPH	O	5	NMOD	O
O	O	1021	1029	infected	infect	B-NP	VBN	O	5	NMOD	O
O	O	1030	1038	patients	patient	I-NP	NNS	O	8	NMOD	O
O	O	1038	1039	,	,	O	,	O	8	P	O
O	O	1040	1044	such	such	B-NP	JJ	O	8	NMOD	O
O	O	1045	1056	enhancement	enhancement	I-NP	NN	O	1	PMOD	O
O	O	1057	1060	may	may	B-VP	MD	O	0	ROOT	O
O	O	1061	1068	further	further	I-VP	RB	O	9	VMOD	O
O	O	1069	1075	impair	impair	I-VP	VB	O	9	VC	O
O	O	1076	1080	host	host	B-NP	NN	O	13	NMOD	O
O	O	1081	1089	immunity	immunity	I-NP	NN	O	11	OBJ	O
O	O	1090	1093	and	and	O	CC	O	9	VMOD	O
O	O	1094	1099	could	could	B-VP	MD	O	9	VMOD	O
O	O	1100	1110	accelerate	accelerate	I-VP	VB	O	15	VC	O
O	O	1111	1114	the	the	B-NP	DT	O	18	NMOD	O
O	O	1115	1121	course	course	I-NP	NN	O	16	OBJ	O
O	O	1122	1124	of	of	B-PP	IN	O	18	NMOD	O
O	O	1125	1128	HIV	HIV	B-NP	NN	O	21	NMOD	O
O	O	1129	1136	disease	disease	I-NP	NN	O	19	PMOD	O
O	O	1136	1137	.	.	O	.	O	9	P	O
